Evidence map›Paper›PMID 37845622›Full record

ArticleBMC cancer2023

Evaluation of rs10811661 polymorphism in CDKN2A / B in colon and gastric cancer.

Maria Beihaghi, Reza Sahebi, Mohammad Reza Beihaghi, Raheleh Khosravi Nessiani, Majedeh Ramian Yarasmi, Sajad Gholamalizadeh, Fatemeh Shahabnavaie, Mitra Shojaei

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Maria BeihaghiDepartment of Biology, Kavian Institute of Higher Education, Mashhad, Iran. maria_beihaghi@yahoo.com.ORCID http://orcid.org/0000-0001-8356-3818
Reza SahebiDepartment of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad Reza BeihaghiDepartment of Public Health, Sheffield Hallam University, Sheffield, South Yorkshire, England.
Raheleh Khosravi NessianiDepartment of Chemical Engineering, Sahand University of Technology, Tabriz, Iran.
Majedeh Ramian YarasmiDepartment of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
Sajad GholamalizadehDepartment of Biology, Kavian Institute of Higher Education, Mashhad, Iran.
Fatemeh ShahabnavaieFaculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Mitra ShojaeiDepartment of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ferdowsi University of Mashhad · IRMashhad University of Medical Sciences · IRYahoo (United Kingdom) · GBSahand University of Technology · IRTabaran Institute of Higher Education · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the causes of colon and gastric cancer is the dysregulation of carcinogenic genes, tumor inhibitors, and micro-RNA. The purpose of this study is to apply rs10811661 polymorphism in CDKN2A /B gene as an effective biomarker of colon cancer and early detection of gastric cancer. As a result,400 blood samples, inclusive of 200 samples from healthy individuals and 200 samples (100 samples from intestinal cancer,100 samples from stomach cancer) from the blood of someone with these cancers, to determine the genotype of genes in healthful and ill people through PCR-RFLP approach and Allelic and genotypic tests of SPSS software. To observe the connection between gastric cancer and bowel cancer risk and genotypes, the t-student test for quantitative variables and Pearson distribution for qualitative variables have been tested and the results have been evaluated using the Chi-square test. The effects confirmed that the highest frequency of TT genotypes is in affected individuals and CC genotype is in healthful individuals. In addition, it confirmed that women were more inclined than men to T3 tumor invasion and most grade II and III colon cancers, and in older sufferers with gastric cancer, the grade of tumor tended to be grade I. Among genetic variety and rs10811661, with invasiveness, there is a tumor size and degree in the affected person. In summary, our findings suggest that the rs10811661 polymorphism of the CDKN2A / B gene is strongly associated with the occurrence of intestinal cancer and stomach is linked to its potential role as a prognostic biomarker for the management of bowel cancer and stomach.

Indexed as

Colorectal NeoplasmsStomach NeoplasmsAgedBiomarkersCase-Control StudiesCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16FemaleGenetic Predisposition to DiseaseGenotypeHumansMalePolymorphism, Single NucleotideBiomarkersCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16BiomarkerCDKN2A / B geneColon cancerGastric CancerPolymorphism rs10811661RFLP-PCRStatistical analysis

Identifiers

PMID37845622
PMCPMC10577985
OpenAlexW4387668963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.